- Home
- ADPT vs BAK Comparison
ADPT vs BAK Comparison
Compare ADPT & BAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- BAK
- Stock Information
- Founded
- ADPT 2009
- BAK 1972
- Country
- ADPT United States
- BAK Brazil
- Employees
- ADPT N/A
- BAK N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- BAK Major Chemicals
- Sector
- ADPT Health Care
- BAK Industrials
- Exchange
- ADPT Nasdaq
- BAK Nasdaq
- Market Cap
- ADPT 1.4B
- BAK 1.4B
- IPO Year
- ADPT 2019
- BAK N/A
- Fundamental
- Price
- ADPT $11.48
- BAK $3.35
- Analyst Decision
- ADPT Strong Buy
- BAK Strong Buy
- Analyst Count
- ADPT 7
- BAK 3
- Target Price
- ADPT $10.57
- BAK $9.75
- AVG Volume (30 Days)
- ADPT 2.2M
- BAK 807.7K
- Earning Date
- ADPT 07-31-2025
- BAK 08-06-2025
- Dividend Yield
- ADPT N/A
- BAK N/A
- EPS Growth
- ADPT N/A
- BAK N/A
- EPS
- ADPT N/A
- BAK N/A
- Revenue
- ADPT $189,527,000.00
- BAK $13,770,122,923.00
- Revenue This Year
- ADPT $24.46
- BAK $18.11
- Revenue Next Year
- ADPT $20.25
- BAK $7.32
- P/E Ratio
- ADPT N/A
- BAK N/A
- Revenue Growth
- ADPT 8.61
- BAK 14.35
- 52 Week Low
- ADPT $3.30
- BAK $2.85
- 52 Week High
- ADPT $12.43
- BAK $7.71
- Technical
- Relative Strength Index (RSI)
- ADPT 63.39
- BAK 41.71
- Support Level
- ADPT $11.17
- BAK $3.16
- Resistance Level
- ADPT $12.43
- BAK $3.87
- Average True Range (ATR)
- ADPT 0.59
- BAK 0.12
- MACD
- ADPT 0.03
- BAK -0.03
- Stochastic Oscillator
- ADPT 62.45
- BAK 26.75
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About BAK Braskem SA ADR
Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.